Young-Ho Lee
Chief Executive Officer bij Immunique Co. Ltd.
Profiel
Young-Ho Lee is currently the Chief Executive Officer at Immunique Co. Ltd.
and a Professor at Hanyang University.
In 2022-2023, he served as an Independent Director at NanoenTek, Inc. He holds a doctorate degree from Hanyang University.
Actieve functies van Young-Ho Lee
| Bedrijven | Functie | Begin |
|---|---|---|
| Hanyang University | Corporate Officer/Principal | - |
Immunique Co. Ltd.
 Immunique Co. Ltd. Miscellaneous Commercial ServicesCommercial Services Immunique Co. Ltd. is a South Korean research company that develops treatments for autoimmune diseases and cancer using immune cells derived from donated blood, such as regulatory T cells and natural killer cells. The company is based in Seongnam-si, South Korea. The company aims to become a leader in the immune cell therapy market. Graft-versus-host disease (GvHD) is a fatal condition that occurs when healthy lymphocytes (mainly T cells) from a blood transfusion are considered foreign by the recipient's body and cause severe side effects in vital organs. The CEO of the company is Young-Ho Lee. | Chief Executive Officer | - |
Eerdere bekende functies van Young-Ho Lee
| Bedrijven | Functie | Einde |
|---|---|---|
| NANOENTEK, INC. | Director/Board Member | 08-09-2023 |
Opleiding van Young-Ho Lee
| Hanyang University | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| NANOENTEK, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Immunique Co. Ltd.
Immunique Co. Ltd. Miscellaneous Commercial ServicesCommercial Services Immunique Co. Ltd. is a South Korean research company that develops treatments for autoimmune diseases and cancer using immune cells derived from donated blood, such as regulatory T cells and natural killer cells. The company is based in Seongnam-si, South Korea. The company aims to become a leader in the immune cell therapy market. Graft-versus-host disease (GvHD) is a fatal condition that occurs when healthy lymphocytes (mainly T cells) from a blood transfusion are considered foreign by the recipient's body and cause severe side effects in vital organs. The CEO of the company is Young-Ho Lee. | Commercial Services |
